FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4285008916> ?p ?o ?g. }

• W4285008916 endingPage "3329" @default.
• W4285008916 startingPage "3319" @default.
• W4285008916 abstract "Background Patients with hematologic malignancies have impaired humoral immunity secondary to their malignancy and its treatment, placing them at risk of severe coronavirus disease‐19 (COVID‐19) infection and reduced response to vaccination. Methods The authors retrospectively analyzed serologic responses to initial and booster COVID‐19 vaccination in 378 patients with hematologic malignancy and subsequently tracked COVID‐19–related outcomes. Results Seroconversion occurred in 181 patients (48%) after initial vaccination; patients who had active malignancy or those who were recently treated with a B‐cell–depleting monoclonal antibody had the lowest rates of seroconversion. For initial nonresponders to vaccination, seroconversion after a booster dose occurred in 48 of 85 patients (56%). The seroconversion rate after the booster was similar for patients on (53%) and off (58%) active therapy ( p = .82). Thirty‐three patients (8.8%) developed a COVID‐19 infection, and there were three COVID‐19–related deaths (0.8%). Although no significant association was observed between postvaccination seroconversion and the incidence of COVID‐19 infection, no patient with seroconversion died from COVID‐19, and no patient who received tixagevimab/cilgavimab ( N = 25) was diagnosed with a COVID‐19 infection. Conclusions Booster vaccinations can promote seroconversion in a significant proportion of patients who are seronegative after the initial vaccination course regardless of the specific vaccine or on/off treatment status at the time of revaccination. Although postvaccination seroconversion may not be associated with a decrease in any (including asymptomatic) COVID‐19 infection, the authors' experience suggested that effective vaccination (including a booster), supplemented by passive immunization using tixagevimab/cilgavimab in case of lack of seroconversion, effectively eliminated the risk of COVID‐19 death in the otherwise high‐risk population. Lay summary Patients with hematologic malignancy, especially lymphoma, have an impaired response to coronavirus disease 2019 (COVID‐19) vaccination. In this single‐institution review, less than one half of the patients studied made detectable antibodies. For those who did not make detectable antibodies after initial vaccination, over one half (65%) were able to produce antibodies after booster vaccination. By the end of February 2022, 33 of the original 378 patients had a documented COVID‐19 infection. The only deaths from COVID‐19 were in those who had undetectable antibodies, and no patient who received prophylactic antibody therapy developed a COVID‐19 infection." @default.
• W4285008916 created "2022-07-12" @default.
• W4285008916 creator A5002239887 @default.
• W4285008916 creator A5011484250 @default.
• W4285008916 creator A5017363028 @default.
• W4285008916 creator A5018900114 @default.
• W4285008916 creator A5020898755 @default.
• W4285008916 creator A5021289915 @default.
• W4285008916 creator A5026649777 @default.
• W4285008916 creator A5048353421 @default.
• W4285008916 creator A5049001978 @default.
• W4285008916 creator A5058210944 @default.
• W4285008916 creator A5061074250 @default.
• W4285008916 creator A5078117289 @default.
• W4285008916 creator A5089512040 @default.
• W4285008916 date "2022-07-11" @default.
• W4285008916 modified "2023-10-15" @default.
• W4285008916 title "Seroconversion and outcomes after initial and booster <scp>COVID</scp>‐19 vaccination in adults with hematologic malignancies" @default.
• W4285008916 cites W2130480915 @default.
• W4285008916 cites W3025062852 @default.
• W4285008916 cites W3043848786 @default.
• W4285008916 cites W3082480386 @default.
• W4285008916 cites W3087063072 @default.
• W4285008916 cites W3090717270 @default.
• W4285008916 cites W3111255098 @default.
• W4285008916 cites W3116049377 @default.
• W4285008916 cites W3119345685 @default.
• W4285008916 cites W3134237532 @default.
• W4285008916 cites W3153508314 @default.
• W4285008916 cites W3162400064 @default.
• W4285008916 cites W3184564817 @default.
• W4285008916 cites W3184620427 @default.
• W4285008916 cites W3191062648 @default.
• W4285008916 cites W3199004246 @default.
• W4285008916 cites W3200272276 @default.
• W4285008916 cites W3216410994 @default.
• W4285008916 cites W3217424271 @default.
• W4285008916 cites W3217661335 @default.
• W4285008916 cites W4200112797 @default.
• W4285008916 cites W4200404916 @default.
• W4285008916 cites W4205483821 @default.
• W4285008916 cites W4206551384 @default.
• W4285008916 cites W4206912062 @default.
• W4285008916 cites W4210450230 @default.
• W4285008916 cites W4221023831 @default.
• W4285008916 doi "https://doi.org/10.1002/cncr.34354" @default.
• W4285008916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35811461" @default.
• W4285008916 hasPublicationYear "2022" @default.
• W4285008916 type Work @default.
• W4285008916 citedByCount "20" @default.
• W4285008916 countsByYear W42850089162022 @default.
• W4285008916 countsByYear W42850089162023 @default.
• W4285008916 crossrefType "journal-article" @default.
• W4285008916 hasAuthorship W4285008916A5002239887 @default.
• W4285008916 hasAuthorship W4285008916A5011484250 @default.
• W4285008916 hasAuthorship W4285008916A5017363028 @default.
• W4285008916 hasAuthorship W4285008916A5018900114 @default.
• W4285008916 hasAuthorship W4285008916A5020898755 @default.
• W4285008916 hasAuthorship W4285008916A5021289915 @default.
• W4285008916 hasAuthorship W4285008916A5026649777 @default.
• W4285008916 hasAuthorship W4285008916A5048353421 @default.
• W4285008916 hasAuthorship W4285008916A5049001978 @default.
• W4285008916 hasAuthorship W4285008916A5058210944 @default.
• W4285008916 hasAuthorship W4285008916A5061074250 @default.
• W4285008916 hasAuthorship W4285008916A5078117289 @default.
• W4285008916 hasAuthorship W4285008916A5089512040 @default.
• W4285008916 hasBestOaLocation W42850089162 @default.
• W4285008916 hasConcept C121332964 @default.
• W4285008916 hasConcept C12590561 @default.
• W4285008916 hasConcept C126322002 @default.
• W4285008916 hasConcept C1276947 @default.
• W4285008916 hasConcept C159654299 @default.
• W4285008916 hasConcept C203014093 @default.
• W4285008916 hasConcept C203165030 @default.
• W4285008916 hasConcept C22070199 @default.
• W4285008916 hasConcept C2777451964 @default.
• W4285008916 hasConcept C2780801004 @default.
• W4285008916 hasConcept C71924100 @default.
• W4285008916 hasConceptScore W4285008916C121332964 @default.
• W4285008916 hasConceptScore W4285008916C12590561 @default.
• W4285008916 hasConceptScore W4285008916C126322002 @default.
• W4285008916 hasConceptScore W4285008916C1276947 @default.
• W4285008916 hasConceptScore W4285008916C159654299 @default.
• W4285008916 hasConceptScore W4285008916C203014093 @default.
• W4285008916 hasConceptScore W4285008916C203165030 @default.
• W4285008916 hasConceptScore W4285008916C22070199 @default.
• W4285008916 hasConceptScore W4285008916C2777451964 @default.
• W4285008916 hasConceptScore W4285008916C2780801004 @default.
• W4285008916 hasConceptScore W4285008916C71924100 @default.
• W4285008916 hasIssue "18" @default.
• W4285008916 hasLocation W42850089161 @default.
• W4285008916 hasLocation W42850089162 @default.
• W4285008916 hasLocation W42850089163 @default.
• W4285008916 hasOpenAccess W4285008916 @default.
• W4285008916 hasPrimaryLocation W42850089161 @default.
• W4285008916 hasRelatedWork W2324037830 @default.
• W4285008916 hasRelatedWork W2385876451 @default.
• W4285008916 hasRelatedWork W3201177512 @default.

• next